Geneoscopy’s Scrape-Free Collection Method for Colorectal Cancer Screening Validated by New Data and Peer-Reviewed Publication
ST. LOUIS, Mo.—October 22, 2025 — Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®
ST. LOUIS, Mo.—August 22, 2025 — Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
Pairing diagnostic innovation with improved patient experience, ColoSense aims to streamline the screening process and increase compliance ST. LOUIS,…
Geneoscopy to Participate in Upcoming Investor Conferences
ST. LOUIS, Mo.—July 17, 2025 — Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences’ ’781 Patent
Decision removes key patent hurdle as Geneoscopy advances ColoSense, its RNA-based noninvasive colorectal cancer screening test ST. LOUIS, Mo.—July…
Modeling Study Published in Clinical Gastroenterology and Hepatology Validates Geneoscopy’s ColoSense® Real-World Screening Impact
ST. LOUIS, Mo.—June 24, 2025 — Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of…
Geneoscopy’s RNA-based ColoSense® Test Included in Latest National Comprehensive Cancer Network® (NCCN) Guidelines
ColoSense recommended as a first-line test for colorectal cancer screening, with a three-year screening interval ST. LOUIS, Mo.—June 3, 2025 —…
Geneoscopy Sibling Co-founders Named Finalists for EY Entrepreneur Of The Year® 2025 Heartland Award
Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future
